Published in Vaccine Weekly, November 20th, 2002
The in vitro and in vivo research data show that these second-generation synthetic CpG immunomodulators have significantly increased metabolic stability as compared to the native compound, and induce higher secretion of disease fighting interleukin-12 (IL-12), with minimal induction of proinflammatory IL-6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly